What Rhophylac 300 Treats: Main Uses and Benefits

The therapeutic domains for Rhophylac 300 include its relevance in preventing Rh-isoimmunization during pregnancy, managing incompatible blood exposure, and providing support for chronic Immune Thrombocytopenic Purpura (ITP).

In pregnancy, its use helps address the risk of symptoms related to systemic imbalance associated with Hemolytic Disease of the Newborn (HDN). For those exposed to incompatible blood, it is applied in clinical settings that involve acute or unstable symptom patterns. Additionally, it is used for managing symptoms that interfere with daily comfort and create noticeable physiological strain in adults with ITP.

“This medication is considered relevant in contexts marked by increased discomfort or risk where additional symptomatic support is needed.”

It contributes to easing the overall symptom load across these conditions. It helps patients cope more steadily with symptom fluctuations, providing supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Support for Bleeding Risk Symptoms

Rhophylac 300 is relevant for easing symptoms associated with a low platelet count, which is linked to heightened physiological activity and increased discomfort in adults with chronic ITP.

Who Can and Cannot Use Rhophylac 300?

The eligibility for Rhophylac 300 is strictly defined by regulatory documents, focusing on immune status and prior medical history.

Populations Allowed to Use the Medicine

Rhophylac 300 is indicated primarily for non-sensitized Rh(D)-negative women during Rh-incompatible pregnancies (ante- and postpartum prophylaxis). It is also approved for Rh(D)-negative individuals after incompatible transfusions and for Rh(D)-positive, non-splenectomized adults with chronic Immune Thrombocytopenic Purpura (ITP).

Absolute Contraindications (Who Must Not Use)

Use is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin products, as well as those with IgA deficiency who have antibodies against IgA. The product is not intended for use in Rh isoimmunization suppression if the person is Rh(D)-positive or already sensitized to the Rh(D) antigen. For postpartum use, it must not be administered to the newborn infant.

Restricted and Conditional Use

For patients with severe thrombocytopenia or bleeding disorders, the intramuscular route is contraindicated, and administration must be intravenous. The intravenous route should also be considered for patients with a Body Mass Index (BMI) ge 30 due to potential reduced efficacy of intramuscular injection. Efficacy and safety have not been investigated in pediatric subjects for Rh isoimmunization prevention or in subjects 65 years and older.

Interactions with other medicines and products

The interaction profile of Rhophylac 300 (Human Anti-D Immunoglobulin) is defined primarily by its function as a passive immunizing agent, which affects both active immunization procedures and certain blood testing results.

Interactions Affecting Immunization and Efficacy

The most significant documented interaction is a pharmacodynamic interference with live attenuated virus vaccines, such as those for measles, mumps, rubella, and varicella. The presence of passive antibodies from Rhophylac 300 may impair the efficacy of these vaccines, preventing the body from developing a full active immune response.

To manage this interaction, regulatory authorities advise that active immunization with these live virus vaccines must generally be postponed for a period of three months following the administration of Human Anti-D Immunoglobulin.

Interference with Laboratory and Serological Tests

Rhophylac 300 can also interact with laboratory procedures. The passive transfer of various antibodies following administration may cause a transitory rise in the patient's blood, which can lead to misleading positive results in serological tests. This is a crucial consideration when interpreting the results of antibody screens, including the direct or indirect Antiglobulin Test (Coombs test).

️ How Rhophylac 300 Works

Rhophylac 300's action is defined by a highly specific, passive immunological mechanism that functions to neutralize foreign cellular material, thereby preventing the establishment of immune memory. The process centers on immediate physical clearance and subsequent suppression of adaptive immune signaling.

---

Targeted Clearance of the RhD Antigen

The drug is composed of IgG antibodies that precisely recognize and bind to the Rhesus D (RhD) antigen on the surface of foreign red blood cells ( RBCs). This binding process, known as opsonization, marks the cells for rapid elimination by the body's natural scavenging system, the Mononuclear Phagocytic System (MPS). The mechanism quickly removes the RhD antigen load from circulation, which results in a reduced antigenic stimulus presented to the adaptive immune system.

---

Inhibition of B Cell Immune Activation

The accelerated removal of the RhD-positive RBCs prevents the host's B lymphocytes from encountering the antigen at a concentration high enough to initiate a response and form permanent antibodies. This action suppresses the initiation of the primary adaptive immune pathway against RhD. The physiological consequence is the functional inhibition of the antigen's immunogenic potential, resulting in a state of transient peripheral quiescence toward the foreign cellular material.

How to Use Rhophylac 300

Rhophylac 300 is a sterile solution for injection supplied in a pre-filled syringe containing 300 mu g (1500 IU) of Human Anti-D Immunoglobulin. Its use follows specific protocols for the suppression of Rh isoimmunization and the treatment of chronic Immune Thrombocytopenic Purpura (ITP).

---

Approved Administration Routes and Form

Administration is strictly by injection, and the approved route depends on the condition:

• Intravenous (IV) Injection: Approved for all indications, including Rh prophylaxis and ITP.
• Intramuscular (IM) Injection: Approved only for Rh prophylaxis. This route is not used for ITP treatment. The solution is ready-to-use and must not be diluted or reconstituted; it should be allowed to reach room temperature before administration.

---

Standard Dosing and Timing

Administration is typically a single, event-based dose under the supervision of a healthcare professional. For Rh isoimmunization, the treatment must be administered within 72 hours of the potentially immunizing event to ensure maximum effect.

Indication	Standard Dose	Timing and Frequency	Contextual Rule
Routine Antepartum Prophylaxis	300 mu g (1500 IU)	Single dose between Week 28-30 of pregnancy.	Fixed dose based on gestational timing.
Postpartum Prophylaxis	300 mu g (1500 IU)	Single dose within 72 hours of birth.	Fixed dose based on event timing.
Chronic ITP	50 mu g (250 IU) per kg	Single administration; IV only.	Weight-based dosing; requires IV monitoring for 8 hours.

For IM administration, large doses (greater than 5 mL) must be divided and injected at different sites.

Research Evidence / Overview of Studies for Rhophylac 300

---

Evidence Structure for Preventing Rh Isoimmunization (Rh Prophylaxis)

Research exploring Anti-D Immunoglobulin, the active component of Rhophylac 300, has been conducted in Rh(D)-negative pregnant women and in Rh(D)-negative individuals after incompatible blood exposure. The evidence primarily includes historical observational studies that examined changes in sensitization rates over time, alongside open-label multi-centre studies that evaluated different methods of administration. Researchers monitored the development of anti-D antibodies and observed the short-term clearance of any Rh(D)-positive red blood cells in the circulation.

Studies described patterns showing that, in the observed populations, a low frequency of Rh sensitization was recorded following the use of Anti-D Immunoglobulin. Results described the clearance of incompatible red blood cells from the bloodstream within a specified time frame. Research highlights measured changes consistent with the expected immunological change when the medication was applied in the studies.

---

Research on Use in Chronic Immune Thrombocytopenic Purpura (ITP)

Research has also examined the use of Rhophylac 300 in certain adults with chronic Immune Thrombocytopenic Purpura (ITP), a condition characterized by fluctuating or episodic manifestations related to low platelet counts. These studies were primarily Phase III clinical trials that focused on a specific subgroup: Rh(D)-positive, non-splenectomized adults. Research explored outcomes related to physical discomfort and physiological strain, specifically monitoring temporary changes in the platelet count and the duration for which any change was sustained.

Studies reported patterns of transient increases in platelet counts following the administration of the medication in a proportion of the studied patients. Findings described that the platelet response measured was short-lived.

---

Areas of Research Uncertainty and Study Limitations

Evidence for both the prophylaxis and ITP indications largely centers on short-term and intermediate-term changes. For ITP, studies observed responses over defined, limited time intervals; consequently, the long-term effects related to maintaining a sustained platelet count are not fully established. Additionally, the findings for ITP are specific and results apply only to the studied populations—Rh(D)-positive, non-splenectomized adults. Evidence quality varies across studies, with some indications relying on decades of clinical observation and others on more recent clinical trials. Finally, research limitations exist regarding the administration of the medication in patient groups like those with obesity, where absorption may vary.

Key Studies & References

1. Rhophylac [Rho(D) Immune Globulin Intravenous (Human)] Prescribing Information
2. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn

Common questions about Rhophylac 300 (FAQ)

---

Q: What is Rhophylac 300 made from?

Rhophylac 300 is made from human plasma—a component of blood donated by healthy individuals. This plasma is specially processed to obtain the active ingredient, which is human anti-D (Rh) immunoglobulin. The official product information notes that the plasma used is thoroughly screened and treated to minimize the theoretical risk of transmitting infectious agents.

---

Q: What is the primary purpose of Rhophylac 300?

The primary purpose of Rhophylac 300, according to regulatory documents, is to prevent an individual's body from making antibodies against Rh-positive red blood cells. This is most commonly indicated for Rh-negative pregnant women who are carrying an Rh-positive baby. It is also used in certain circumstances involving incompatible blood transfusions in Rh-negative patients.

---

Q: Does Rhophylac 300 treat a condition, or is it a preventative measure?

Regulatory sources generally describe Rhophylac 300 as a preventative measure rather than a treatment for an existing condition. Its function is to help prevent the immune system of an Rh-negative person from developing a long-term reaction to Rh-positive blood cells. Official information states that it helps prevent a condition known as Rh-sensitization.

---

Q: Can I take Rhophylac 300 if I am breastfeeding?

Official product information indicates that no adverse effects are anticipated for the breastfed newborn when Rhophylac 300 is used by the mother. This is because the active ingredient, anti-D immunoglobulin, is a natural component of human milk. Regulatory documents do not contain any restrictions on using this medication during lactation.

---

Q: What are immunoglobulins, and how do they work in this medicine?

Immunoglobulins, also known as antibodies, are proteins the body naturally uses as part of its immune defense system. In Rhophylac 300, the specific immunoglobulin is anti-D, which is introduced passively. Regulatory documents state it is indicated to help clear Rh-positive red blood cells from the patient's system before the body's own immune system can create a long-lasting sensitization response.

---

Q: Where is Rhophylac 300 administered in the body?

Rhophylac 300 is administered into the body through an injection by a healthcare professional. The official product information specifies that it can be given either intramuscularly (into a muscle) or intravenously (into a vein). The official label specifies that the route of administration is selected by the prescribing healthcare professional based on the patient's specific needs.

---

Q: What information does the label provide about a missed administration?

Regulatory documents mention that if an administration is missed, the full protective effect of the medicine may not be achieved. Because the timing of administration is crucial for its preventative effect, official product information indicates that in the event of a missed administration, consultation with a healthcare provider is necessary to determine the appropriate next step.

How to Store and Dispose of Rhophylac 300

Rhophylac 300 must be stored strictly within the specified temperature range to maintain its stability and effectiveness. The product should be kept in a refrigerator, at a temperature between 2 C and 8 C (36 F and 46 F).

Key Storage and Handling Requirements:

• Do not freeze the pre-filled syringe.
• Keep the syringe in its original outer carton to protect it from light.
• Before use, allow the product to reach room temperature.
• Visually inspect the solution; do not use if it appears cloudy, discolored, or contains particles.
• Rhophylac 300 is for single use only. Any unused portion must be properly discarded.

Disposal Instructions:

Dispose of any unused, expired, or waste material in accordance with local regulatory requirements. Do not dispose of this medication via household waste or wastewater unless specifically instructed to do so.